DNA icon

Congenital Fibrosis of Extraocular Muscles (Ocular Motility Disorder) Type 3A via the TUBB3 Gene

Summary and Pricing

Test Method

Exome Sequencing with CNV Detection
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
TUBB3 81479 81479,81479 $990
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
8971TUBB381479 81479,81479 $990 Order Options and Pricing

Pricing Comments

Our favored testing approach is exome based NextGen sequencing with CNV analysis. This will allow cost effective reflexing to PGxome or other exome based tests. However, if full gene Sanger sequencing is desired for STAT turnaround time, insurance, or other reasons, please see link below for Test Code, pricing, and turnaround time information.

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Click here for costs to reflex to whole PGxome (if original test is on PGxome Sequencing platform).

Click here for costs to reflex to whole PGnome (if original test is on PGnome Sequencing platform).

The Sanger Sequencing method for this test is NY State approved.

For Sanger Sequencing click here.

Turnaround Time

3 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.

Targeted Testing

For ordering sequencing of targeted known variants, go to our Targeted Variants page.


Genetic Counselors


  • Dana Talsness, PhD

Clinical Features and Genetics

Clinical Features

Congenital fibrosis of extraocular muscles (CFEOM) is an eye movement disorder characterized mainly by non-progressive, restrictive ophthalmoplegia of the extraocular muscles (EOM) and congenital blepharoptosis (Heidary et al. 2008). Congenital fibrosis of extraocular muscles (CFEOM) is a heterogeneous disorder. Depending on the gene, the disease has been categorized into different types. CFEOM1 (due to KIF21A variants), CFEOM2 (due to ARIX variants), CFEOM3A (due to TUBB3 variants), CFEOM3B (due to KIF21A variants), and CFEOM4, CFEOM5 (no genes identified yet) (Oystreck et al. 2011; Traboulsi 2004).

CFEOM3A affected patients may have additional neurological signs or symptoms such as intellectual disability, social disability, facial weakness, and progressive sensorimotor axonal polyneuropathy (Andrews et al. 1993).


CFEOM3A is an autosomal dominant disorder, which is due to heterozygous variants in TUBB3. TUBB3 encodes neuron-specific beta-tubulin subunit, which is required for axon guidance and maintenance in mammals (Poirier et al. 2010; Tischfield et al. 2010). In vitro studies using yeast have shown that the TUBB3 causative variants can impair tubulin heterodimer formation and disrupt the interaction of microtubules with kinesin motors. This in turn leads to innervation abnormalities in the EOM during the development of oculomotor and/or trochlear nerves (Tischfield et al. 2010). CFEOM3A is variable, asymmetrical, and variably penetrant (~90%) (Doherty et al 1999). A mutation screen involving 29 unrelated families revealed that 13 had eight TUBB3 pathogenic variants and all occurred de novo (Tischfield et al. 2010). Severe phenotype has been reported in patients with de novo mutations in TUBB3 (Poirier et al. 2010). So far only missense variants have shown to be causative for TUBB3-associated disorders (Human Gene Mutation Database).

Clinical Sensitivity - Sequencing with CNV PGxome

Predicting clinical sensitivity for the TUBB3 gene is challenging due to genetic heterogeneity of Congenital fibrosis of extraocular muscles. However, analytical sensitivity should be high as all the reported variants are detectable by sequencing. TUBB3 mutation screening in 6 unrelated individuals with sporadic CFEOM3A identified de novo pathogenic variants in all the affected patients (Tischfield et al. 2010).

Testing Strategy

This test provides full coverage of all coding exons of the TUBB3 gene plus 10 bases of flanking noncoding DNA in all available transcripts along with other non-coding regions in which pathogenic variants have been identified at PreventionGenetics or reported elsewhere. We define full coverage as >20X NGS reads or Sanger sequencing. PGnome panels typically provide slightly increased coverage over the PGxome equivalent. PGnome sequencing panels have the added benefit of additional analysis and reporting of deep intronic regions (where applicable).

Dependent on the sequencing backbone selected for this testing, discounted reflex testing to any other similar backbone-based test is available (i.e., PGxome panel to whole PGxome; PGnome panel to whole PGnome).

Indications for Test

Patients with congenital abnormalities of eye movements are candidates ((Oystreck et al. 2011; http://novel.utah.edu/diseases/rare-registry/view/Unusual_Congenital_Ocular_Motility_Disorders).


Official Gene Symbol OMIM ID
TUBB3 602661
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


  • Andrews CV et al. 2011. Congenital Fibrosis of the Extraocular Muscles. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong C-T, Smith RJ, and Stephens K, editors. GeneReviews(), Seattle (WA): University of Washington, Seattle. PubMed ID: 20301522
  • Doherty EJ. et al. 1999. Investigative ophthalmology & visual science. 40: 1687-94. PubMed ID: 10393037
  • Heidary et al. 2008. Semin Ophthalmol 23: 38. PubMed ID: 18214786
  • Human Gene Mutation Database (Bio-base).
  • NANOS Collection of Unusual Congenital Ocular Motility Disorders and Strabismus
  • Oystreck DT. et al. 2011. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society. 31: 69-77. PubMed ID: 21317732
  • Poirier K. et al. 2010. Human molecular genetics. 19: 4462-73. PubMed ID: 20829227
  • Tischfield MA. et al. 2010. Cell. 140: 74-87. PubMed ID: 20074521
  • Traboulsi EI. 2004. Transactions of the American Ophthalmological Society. 102: 373-89. PubMed ID: 15747768


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.

Specimen Types

Specimen Requirements and Shipping Details

PGxome (Exome) Sequencing Panel

PGnome (Genome) Sequencing Panel

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard